Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics OCF/Debt

The Operating Cash Flow to Debt Ratio of Aspira Pathlab & Diagnostics (540788.BO) as of Nov 18, 2026 is 57.17 %. In the previous year, Operating Cash Flow to Debt Ratio was 37.85 % — a change of 51.03% (higher).

OCF/Debt

57.17 %

YoY

51.03%

Last updated:

Operating Cash Flow to Debt Ratio of Aspira Pathlab & Diagnostics is 2025 57.17 % . Operating Cash Flow to Debt Ratio of Aspira Pathlab & Diagnostics was 2024 37.85 % . It decreases by 51.03% higher compared to the previous year.

The Aspira Pathlab & Diagnostics OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
-42.38 INR
Jan 1, 2019
-44.61 INR
Jan 1, 2020
-23.35 INR
Jan 1, 2021
272.18 INR
Jan 1, 2022
51.78 INR
Jan 1, 2023
-0.36 INR
Jan 1, 2024
37.85 INR
Jan 1, 2025
57.17 INR
The Aspira Pathlab & Diagnostics OCF/Debt history
YEAROCF/DebtYoY
57.17 %+51.03%
37.85 %-10,552.08%
-0.36 %-100.70%
51.78 %-80.97%
272.18 %-1,265.90%
-23.35 %-47.67%
-44.61 %+5.25%
-42.38 %+139.63%
-17.69 %+27.12%
-13.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments. Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

Operating Cash Flow to Debt Ratio of Aspira Pathlab & Diagnostics is 57.17 % in 2025.

Operating Cash Flow to Debt Ratio of Aspira Pathlab & Diagnostics changed from 37.85 % to 57.17 %, representing a 51.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Aspira Pathlab & Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Aspira Pathlab & Diagnostics

All Key Metrics — Aspira Pathlab & Diagnostics